Literature DB >> 24231510

Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets.

Eugenio Barone1, Fabio Di Domenico2, D Allan Butterfield3.   

Abstract

Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by severe cognitive impairment, inability to perform activities of daily living and mood changes. Statins, long known to be beneficial in conditions where dyslipidemia occurs by lowering serum cholesterol levels, also have been proposed for use in neurodegenerative conditions, including AD. However, it is not clear that the purported effectiveness of statins in neurodegenerative disorders is directly related to cholesterol-lowering effects of these agents; rather, the pleiotropic functions of statins likely play critical roles. The aim of this review is to provide an overview on the new discoveries about the effects of statin therapy on the oxidative and nitrosative stress levels as well as on the modulation of the heme oxygenase/biliverdin reductase (HO/BVR) system in the brain. We propose a novel mechanism of action for atorvastatin which, through the activation of HO/BVR-A system, may contribute to the neuroprotective effects thus suggesting a potential therapeutic role in AD and potentially accounting for the observation of decreased AD incidence with persons on statin.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Biliverdin reductase; Cognition; Heme oxygenase; Oxidative stress; Statin

Mesh:

Substances:

Year:  2013        PMID: 24231510      PMCID: PMC3972306          DOI: 10.1016/j.bcp.2013.10.030

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  155 in total

1.  Causes and consequences of oxidative stress in Alzheimer's disease.

Authors:  Mark A Smith; George Perry; William A Pryor
Journal:  Free Radic Biol Med       Date:  2002-06-01       Impact factor: 7.376

2.  Reduced risk of incident AD with elective statin use in a clinical trial cohort.

Authors:  D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Donald J Connor; Lisa M Sparks; Carolyn Liebsack
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

Review 3.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 4.  Statins for the treatment of dementia.

Authors:  Bernadette McGuinness; John O'Hare; David Craig; Roger Bullock; Reem Malouf; Peter Passmore
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

Review 5.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress.

Authors:  D Allan Butterfield; Christopher M Lauderback
Journal:  Free Radic Biol Med       Date:  2002-06-01       Impact factor: 7.376

6.  Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin.

Authors:  Karin M Thelen; Katharina M Rentsch; Ursula Gutteck; Maura Heverin; Maria Olin; Ulla Andersson; Arnold von Eckardstein; Ingemar Björkhem; Dieter Lütjohann
Journal:  J Pharmacol Exp Ther       Date:  2005-11-10       Impact factor: 4.030

Review 7.  The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches.

Authors:  Carl W Cotman; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

Review 8.  Cholesterol and Alzheimer's disease: a still poorly understood correlation.

Authors:  Roberta Ricciarelli; Elisa Canepa; Barbara Marengo; Umberto M Marinari; Giuseppe Poli; Maria A Pronzato; Cinzia Domenicotti
Journal:  IUBMB Life       Date:  2012-11-02       Impact factor: 3.885

9.  Biliverdin reductase: more than a namesake - the reductase, its Peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C.

Authors:  Peter E M Gibbs; Cicerone Tudor; Mahin D Maines
Journal:  Front Pharmacol       Date:  2012-03-13       Impact factor: 5.810

10.  Pravastatin and cognitive function in the elderly. Results of the PROSPER study.

Authors:  Stella Trompet; Peter van Vliet; Anton J M de Craen; Jelle Jolles; Brendan M Buckley; Michael B Murphy; Ian Ford; Peter W Macfarlane; Naveed Sattar; Chris J Packard; David J Stott; Jim Shepherd; Eduard L E M Bollen; Gerard J Blauw; J Wouter Jukema; Rudi G J Westendorp
Journal:  J Neurol       Date:  2009-08-04       Impact factor: 4.849

View more
  20 in total

Review 1.  Are microRNAs the Molecular Link Between Metabolic Syndrome and Alzheimer's Disease?

Authors:  Juan F Codocedo; Juvenal A Ríos; Juan A Godoy; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2015-05-15       Impact factor: 5.590

Review 2.  An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.

Authors:  Xiaoling Zhou; Yifei Li; Xiaozhe Shi; Chun Ma
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

3.  Atorvastatin Protects from Aβ1-40-Induced Cell Damage and Depressive-Like Behavior via ProBDNF Cleavage.

Authors:  Fabiana K Ludka; Maurício P Cunha; Tharine Dal-Cim; Luisa Bandeira Binder; Leandra C Constantino; Caio M Massari; Wagner C Martins; Ana Lúcia S Rodrigues; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2016-10-05       Impact factor: 5.590

Review 4.  The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration.

Authors:  Seyed Soheil Saeedi Saravi; Seyed Sobhan Saeedi Saravi; Alireza Arefidoust; Ahmad Reza Dehpour
Journal:  Metab Brain Dis       Date:  2017-06-03       Impact factor: 3.584

Review 5.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

6.  Atorvastatin Attenuates Cognitive Deficits and Neuroinflammation Induced by Aβ1-42 Involving Modulation of TLR4/TRAF6/NF-κB Pathway.

Authors:  Shan Wang; Xiaowei Zhang; Liuyu Zhai; Xiaona Sheng; Weina Zheng; Hongshan Chu; Guohua Zhang
Journal:  J Mol Neurosci       Date:  2018-02-07       Impact factor: 3.444

7.  Role of inflammatory, oxidative, and ER stress signaling in the neuroprotective effect of atorvastatin against doxorubicin-induced cognitive impairment in rats.

Authors:  Noha M Mounier; Sara A Wahdan; Amany M Gad; Samar S Azab
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-03-23       Impact factor: 3.000

Review 8.  HSV-1 and Alzheimer's disease: more than a hypothesis.

Authors:  Roberto Piacentini; Giovanna De Chiara; Domenica D Li Puma; Cristian Ripoli; Maria E Marcocci; Enrico Garaci; Anna T Palamara; Claudio Grassi
Journal:  Front Pharmacol       Date:  2014-05-07       Impact factor: 5.810

9.  A Surgical Method to Improve the Homeostasis of CSF for the Treatment of Alzheimer's Disease.

Authors:  Yang Qin; Jian W Gu
Journal:  Front Aging Neurosci       Date:  2016-11-02       Impact factor: 5.750

10.  Atorvastatin Alleviates Experimental Diabetic Cardiomyopathy by Regulating the GSK-3β-PP2Ac-NF-κB Signaling Axis.

Authors:  Xiao-Min Ren; Guang-Feng Zuo; Wen Wu; Jie Luo; Peng Ye; Shao-Liang Chen; Zuo-Ying Hu
Journal:  PLoS One       Date:  2016-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.